A peptide NK1 receptor agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

[Sar9, Met(O2)11]-Substance P (trifluoroacetate salt)

Item No. 30106

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(S)-2-((S)-1-(L-arginyl-L-prolyl-L-lysyl)pyrrolidine-2-carboxamido)-N1-((S)-5-amino-1-(((S)-1-(((S)-1-((2-(((S)-1-(((S)-1-amino-4-(methylsulfonyl)-1-oxobutan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1,5-dioxopentan-2-yl)pentanediamide
Synonyms
  • Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-{Sar}-Leu-Met[O2]-NH2
  • [Sar9, Met(O2)11]-SP
Molecular Formula
C64H100N18O15S • XCF3COOH
Formula Weight
1393.7
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Water: 1 mg/ml
SMILES
O=C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC2=CC=CC=C2)C(N(C)CC(N[C@@H](CC(C)C)C(N[C@@H](CCS(C)(=O)=O)C(N)=O)=O)=O)=O)=O)=O)=O)[C@H]3N(C([C@@H](NC([C@H]4N(C([C@@H](N)CCCNC(N)=N)=O)CCC4)=O)CCCCN)=O)CCC3.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C64H100N18O15S.C2HF3O2/c1-38(2)34-46(57(89)74-42(54(69)86)28-33-98(4,96)97)73-53(85)37-80(3)62(94)48(36-40-18-9-6-10-19-40)79-58(90)47(35-39-16-7-5-8-17-39)78-56(88)43(24-26-51(67)83)75-55(87)44(25-27-52(68)84)76-59(91)50-23-15-32-82(50)63(95)45(21-11-12-29-65)77-60(92)49-22-14-31-81(49)61(93)41(66)20-13-30-72-64(70)71;3-2(4,5)1(6)7/h5-10,16-19,38,41-50H,11-15,20-37,65-66H2,1-4H3,(H2,67,83)(H2,68,84)(H2,69,86)(H,73,85)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,88)(H,79,90)(H4,70,71,72);(H,6,7)/t41-,42-,43-,44-,45-,46-,47-,48-,49-,50-;/m0./s1
InChi Key
VDZDOTCGVUBCPG-LYQMAKBCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $148

    Add
    Product Description

    [Sar9, Met(O2)11]-Substance P (Sar-SP) is a peptide agonist of the neurokinin-1 (NK1) receptor.1 It is selective for NK1 over NK2 and NK3 receptors. Sar-SP induces inositol phosphate formation in U373MG glioblastoma cells with an EC50 value of 3.8 nM, an effect that can be blocked by the NK1 receptor antagonist SR 140333.2 It induces contractions in isolated human bronchi when used at concentrations of 3, 100, and 1,000 nM.3 Sar-SP (10, 25, 65, and 100 pmol/animal, i.c.v.) increases mean arterial pressure and heart rate in conscious rats.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Regoli, D., Drapeau, G., Dion, S., et al. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol. Sci. 9(8), 290-295 (1988).

    2. Oury-Donat, F., Thurneyssen, L.O., Gauthier, T., et al. SR 1140333, a novel, selective, and potent nonpeptide antagonist of the NKl tachykinin receptor: Characterization on the U373MG cell line. J. Neurochem. 62(4), 1399-1407 (1994).

    3. Barchasz, E., Naline, E., Molimard, M., et al. Interleukin-1β-induced hyperresponsiveness to Sar9,Met(O2)11 substance x 2 P in isolated human bronchi. Eur. J. Pharmacol. 379(1), 87-95 (1999).

    4. Cellier, E., Barbot, L., Iyengar, S., et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br. J. Pharmacol. 127(3), 717-728 (1999).